These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28387109)

  • 21. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
    Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT
    Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Tellor KB; Van Tuyl JS; Armbruster AL
    Ther Clin Risk Manag; 2016; 12():667-74. PubMed ID: 27217759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Hurst KV; O'Callaghan JM; Handa A
    Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
    Salazar DE; Mendell J; Kastrissios H; Green M; Carrothers TJ; Song S; Patel I; Bocanegra TS; Antman EM; Giugliano RP; Kunitada S; Dornseif B; Shi M; Tachibana M; Zhou S; Rohatagi S
    Thromb Haemost; 2012 May; 107(5):925-36. PubMed ID: 22398655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
    Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Mercuri M; Curt V; Betcher J; Grip L; Cange AL; Crompton AE; Murphy SA; Deenadayalu N; Antman EM
    J Am Coll Cardiol; 2014 Aug; 64(6):576-84. PubMed ID: 25104527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
    Deedwania PC; Huang GW
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Edoxaban tosylate.
    Am J Cardiovasc Drugs; 2011; 11(2):129-35. PubMed ID: 21446778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
    O'Donoghue ML; Ruff CT; Giugliano RP; Murphy SA; Grip LT; Mercuri MF; Rutman H; Shi M; Kania G; Cermak O; Braunwald E; Antman EM
    Eur Heart J; 2015 Jun; 36(23):1470-7. PubMed ID: 25687352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
    Aspromonte N; Colivicchi F
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):113-122. PubMed ID: 27819149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban.
    Masjuan J; DeFelipe A
    Int J Neurosci; 2017 Aug; 127(8):716-725. PubMed ID: 27586690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GYH; Al-Saady N; Ezekowitz MD; Banach M; Goette A
    Am Heart J; 2017 Nov; 193():16-22. PubMed ID: 29129251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK.
    Clay E; Jamotte A; Verhamme P; Cohen AT; Van Hout BA; Gumbs P
    J Mark Access Health Policy; 2018; 6(1):1495974. PubMed ID: 30034645
    [No Abstract]   [Full Text] [Related]  

  • 37. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety of edoxaban for treating atrial fibrillation.
    Hammwöhner M; Goette A
    Expert Opin Drug Saf; 2017 Nov; 16(11):1295-1303. PubMed ID: 28862063
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.